Please login to the form below

Not currently logged in

Zealand adds two observers to board of directors

Martin Nicklasson and Catherine Moukheibir join the firm
Martin Nicklasson

Denmark-based pharma company Zealand Pharma has added Dr Martin Nicklasson and Catherine Moukheibir the company's board of directors in the role of observers.

The announcement comes just days after the pharma company revealed Britt Meelby Jensen as its new CEO.

Nicklasson has held various executive VP positions at AstraZeneca and was president and CEO of BioVitrum and Swedish Orphan Biovitrum. He is also chairman of the board of Basilea, Orexo and Farma Holding.

Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking. She is currently a non-executive board member of Creabilis and Ablynx.

Daniel Ellens, chairman of the Zealand board of directors, said: “They provide important and broad-based experience from public life science companies and are important additions to the competences on the board as we prepare for the next steps in Zealand's growth strategy as a maturing biotech company.”

12th November 2014

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Haseeb Ahmad
Can value-based healthcare take off and reach for the skies?
Are companies willing to contribute to the change in the healthcare system?...
Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...